SineuGene
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A gene therapy company developing AAV-based treatments for neurological and rare diseases.
NeuroscienceRare Disease
Technology Platform
Proprietary AAV vector engineering platform designed for enhanced delivery and expression in the central nervous system.
Opportunities
Potential to achieve breakthrough therapy status for devastating rare neurological conditions with no effective treatments.
Risk Factors
Faces substantial scientific risk related to vector efficacy and safety, as well as the long development timelines and high costs of CNS gene therapy trials.
Competitive Landscape
Competes in the high-risk, high-reward global gene therapy arena, where scientific and clinical hurdles for neurological diseases are particularly significant.